Results 291 to 300 of about 2,086,080 (370)

Impact of Asymptomatic Intracranial Hemorrhage on Outcome After Endovascular Stroke Treatment

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Endovascular treatment (EVT) achieves high rates of recanalization in acute large‐vessel occlusion (LVO) stroke, but functional recovery remains heterogeneous. While symptomatic intracranial hemorrhage (sICH) has been well studied, the prognostic impact of asymptomatic intracranial hemorrhage (aICH) after EVT is less certain ...
Shihai Yang, Chengsong Yue, Zhuang Li, Xiaolei Shi, Haoxuan Zhu, Jie Yang, Linyu Li, Jiaxing Song, Shitao Fan, Gaoming Li, Wenzhe Sun, Zhixian Ye, Jiacheng Huang, Dahong Yang, Jinfu Ma, Xu Xu, Zhixi Wang, Lilan Wang, Guojian Liu, Fengli Li, Changwei Guo, Li Qi, Wenjie Zi   +22 more
wiley   +1 more source

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Accessing brain magnetic resonance imaging (MRI) can be challenging, especially for underserved patients, which may lead to disparities in neurological diagnosis. Method This mixed‐methods study enrolled adults with one of four neurological disorders: mild cognitive impairment or dementia of the Alzheimer type, multiple sclerosis ...
Maya L. Mastick, Nomin Enkhtsetseg, Joseph Sadok, Matheus Mochetti, Annabel Sorby Adams, Jennifer Guo, Cristina Trapaga Hacker, Isabella Gomez Hjerthen, Seungwon Lee, Siddharth Satish, Andrew S. Ham, Justin Hill, Denis Balaban, Kevin Kyle, Rebecca L. Gillani, Marcelo Matiello, Aleksandar Videnovic, Eric C. Klawiter, W. Taylor Kimberly, Farrah J. Mateen   +19 more
wiley   +1 more source

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)

, 2018
Celine-Lea Halioua-Haubold, Jasleen K. Jolly, R Pinedo Villanueva, David Brindley, Robert E. MacLaren   +4 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Utilities and Quality-Adjusted Life Years

International Journal of Technology Assessment in Health Care, 1989
Utilities and quality-adjusted life years (QALYs) are reviewed, with particular focus on their use in technology assessment. This article provides a broad overview and perspective on these two techniques and their interrelationship, with reference to other sources for details of implementation.
G W, Torrance, D, Feeny
openaire   +3 more sources

Quality Adjusted Life Years

Definitions, 2020
K. Frick
openaire   +2 more sources

Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review.

Health Affairs, 2021
Researchers and policy makers in the US are exploring the implementation of health technology assessment and value-based pricing to negotiate drug prices and limit spending.
L. Rand, A. Kesselheim
semanticscholar   +1 more source

Quality-Adjusted Life Years (QALYs)

Encyclopedia of Behavioral Medicine, 2013
J. Rick Turner, Maartje Wit, Tibor Hajos, Maartje Wit, M. Bryant Howren, Salvatore Insana, Matthew A. Simonson   +6 more
openaire   +2 more sources

Quality-Adjusted Life Years

Practical Neurology, 2008
Many health systems now use cost-effectiveness analysis to decide which interventions and programmes to fund. A key issue for such decision making is how to measure health outcomes from interventions to reflect changes in both health-related quality of life and life expectancy.
Yolanda, Bravo Vergel, Mark, Sculpher
openaire   +3 more sources

Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia

Multiple Sclerosis, 2020
Objectives: To quantify life expectancy (LE), quality-adjusted life years (QALYs) and total lifetime societal costs for a hypothetical cohort of Australians with multiple sclerosis (MS).
A. Palmer, I. van der Mei, B. Taylor, P. Clarke, S. Simpson, H. Ahmad   +5 more
semanticscholar   +1 more source